https://www.ynetnews.com/health_science/article/h1wxtatn0
Key concerns raised by the panel included the study design, potential for drug abuse, risks outweighing benefits, lack of diversity in trials, missing patient data, and potential bias from therapists and facilitators.
One of two possibilities
ReplyDelete1) This is really, really bad because the FDA has a habit of approving anyone on the flimsiest of evidence
2) The psylocibin folks paid them off